Clinical trials: Uterine Fibroids With Menorrhagia, active
Menorrhagia, Uterine Fibroids
to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia
The goal of this clinical trial was to determine whether the investigational drug KLH-2109 is effective for treating excessive menstrual bleeding in patients with uterine fibroids.
- Trial name
- NCT07378098
- Where
- South Korea
- Volunteers
- 254 people
- Sponsor
- JW Pharmaceutical
Uterine Fibroids With Menorrhagia
Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia
Objective This study evaluates whether CMS-D002 capsules are effective in treating menorrhagia in participants with uterine fibroids associated with menorrhagia.
- Trial name
- NCT07402369
- Testing
- CMS-D002 Capsules 10 mg, CMS-D002 Capsules 25 mg, CMS-D002 Capsules 50 mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Kangzhe Biotechnology Co., Ltd.
Heavy Menstrual Bleeding, Uterine Fibroids
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
The goal of this clinical trial is to determine the benefit of relugolix 40 milligrams (mg) once a day compared with placebo in heavy menstrual bleeding associated with uterine fibroids.
- Trial name
- NCT06671548
- Testing
- Relugolix
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Uterine Fibroids, Endometriosis
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in…
- Trial name
- NCT05862272
- Testing
- Relugolix Combination Tablet
- Where
- 120 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH